Sabatine, Marc S.

Cognitive function in a randomized trial of evolocumab

Giugliano, R. P., Mach, F., Zavitz, K., Kurtz, C., Im, K., Kanevsky, E., Schneider, J., Wang, H., Keech, A., Pedersen, T. R., et al. (2017) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthDementia and Cognitive Impairment Research

Cited by 492

Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial

Zelniker, T. A., Bonaca, M. P., Furtado, R. H. M., Mosenzon, O., Kuder, J. F., Murphy, S. A., Bhatt, D. L., Leiter, L. A., McGuire, D. K., Wilding, J. P. H., et al. (2020) · Circulation

Diabetes Treatment and ManagementAtrial Fibrillation Management and Outcomes

Cited by 459

A Trial to Evaluate the Effect of the Sodium–Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Morbidity and Mortality in Patients with Heart Failure and Reduced Left Ventricular Ejection Fraction (DAPA-HF)

McMurray, J. J. V., DeMets, D. L., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Langkilde, A. M., Martinez, F. A., Bengtsson, O., Ponikowski, P., Sabatine, M. S., et al. (2019) · European Journal of Heart Failure

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 433

Metabolic signatures of exercise in human plasma

Lewis, G. D., Farrell, L., Wood, M. J., Martinovic, M., Arany, Z., Rowe, G. C., Souza, A., Cheng, S., McCabe, E. L., Yang, E., et al. (2010) · Science Translational Medicine

Metabolomics and Mass Spectrometry StudiesCardiovascular and exercise physiology

Cited by 432

Long-term evolocumab in patients with established atherosclerotic cardiovascular disease

O’Donoghue, M. L., Giugliano, R. P., Wiviott, S. D., Atar, D., Keech, A., Kuder, J. F., Im, K., Murphy, S. A., Flores-Arredondo, J. H., López, J. A. G., et al. (2022) · Circulation

Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular Diseases

Cited by 410

Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease

Sabatine, M. S., Morrow, D. A., Jablonski, K. A., Rice, M. M., Warnica, J. W., Domanski, M. J., Hsia, J., Gersh, B. J., Rifai, N., Ridker, P. M., et al. (2007) · Circulation

Lipoproteins and Cardiovascular HealthInflammatory Biomarkers in Disease Prognosis

Cited by 385

Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial

Kosiborod, M. N., Jhund, P. S., Docherty, K. F., Diez, M., Petrie, M. C., Verma, S., Nicolau, J. C., Merkely, B., Kitakaze, M., DeMets, D. L., et al. (2020) · Circulation

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 350

2019 ESC/EAS Guidelines for themanagement of dyslipidaemias: lipid modification to reduce cardiovascular risk

Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · Russian Journal of Cardiology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 325

Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials

Gencer, B., Marston, N. A., Im, K., Cannon, C. P., Sever, P., Keech, A., Braunwald, E., Giugliano, R. P., & Sabatine, M. S. (2020) · The Lancet

Lipoproteins and Cardiovascular HealthAntiplatelet Therapy and Cardiovascular Diseases

Cited by 318

Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF

Jhund, P. S., Solomon, S. D., Docherty, K. F., Heerspink, H. J. L., Anand, I. S., Böhm, M., Chopra, V., de Boer, R. A., Desai, A. S., Ge, J., et al. (2021) · Circulation

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 307

Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk

Ference, B. A., Kastelein, J. J. P., Ginsberg, H. N., Chapman, M. J., Nicholls, S. J., Ray, K. K., Packard, C. J., Laufs, U., Brook, R. D., Oliver-Williams, C., et al. (2017) · JAMA

Lipoproteins and Cardiovascular HealthGenetic Associations and Epidemiology

Cited by 304

2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease

Levine, G. N., Bates, E. R., Bittl, J. A., Brindis, R. G., Fihn, S. D., Fleisher, L. A., Granger, C. B., Lange, R. A., Mack, M. J., Mauri, L., et al. (2016) · The Journal of Thoracic and Cardiovascular Surgery

Antiplatelet Therapy and Cardiovascular DiseasesCoronary Interventions and Diagnostics

Cited by 304

Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials

Marston, N. A., Giugliano, R. P., Im, K., Silverman, M. G., O’Donoghue, M. L., Wiviott, S. D., Ference, B. A., & Sabatine, M. S. (2019) · Circulation

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 301

Inflammatory and Cholesterol Risk in the FOURIER Trial

Bohula, E. A., Giugliano, R. P., Leiter, L. A., Verma, S., Park, J.-G., Sever, P. S., Lira Pineda, A., Honarpour, N., Wang, H., Murphy, S. A., et al. (2018) · Circulation

Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular Diseases

Cited by 280

Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients

Bohula, E. A., Wiviott, S. D., McGuire, D. K., Inzucchi, S. E., Kuder, J., Im, K., Fanola, C. L., Qamar, A., Brown, C., Budaj, A., et al. (2018) · New England Journal of Medicine

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 265

Association of Apolipoprotein B–Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis

Marston, N. A., Giugliano, R. P., Melloni, G. E. M., Park, J.-G., Morrill, V., Blazing, M. A., Ference, B., Stein, E., Stroes, E. S., Braunwald, E., et al. (2022) · JAMA Cardiology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 262

Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF

Curtain, J. P., Docherty, K. F., Jhund, P. S., Petrie, M. C., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., et al. (2021) · European Heart Journal

Heart Failure Treatment and ManagementCardiac electrophysiology and arrhythmias

Cited by 256

Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER

Sabatine, M. S., De Ferrari, G. M., Giugliano, R. P., Huber, K., Lewis, B. S., Ferreira, J., Kuder, J. F., Murphy, S. A., Wiviott, S. D., Kurtz, C. E., et al. (2018) · Circulation

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 255

Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial

O’Donoghue, M. L., Glaser, R., Cavender, M. A., Aylward, P. E., Bonaca, M. P., Budaj, A., Davies, R. Y., Dellborg, M., Fox, K. A. A., Gutierrez, J. A. T., et al. (2016) · JAMA

Acute Myocardial Infarction ResearchCardiac Fibrosis and Remodeling

Cited by 249

The Dapagliflozin And Prevention of Adverse-Outcomes in Heart Failure (DAPA-HF) Trial: Baseline Characteristics

McMurray, J. J. V., DeMets, D. L., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Langkilde, A. M., Martinez, F. A., Bengtsson, O., Ponikowski, P., Sabatine, M. S., et al. (2019) · European Journal of Heart Failure

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 222

Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS–TIMI 54

Bhatt, D. L., Bonaca, M. P., Bansilal, S., Angiolillo, D. J., Cohen, M., Storey, R. F., Im, K., Murphy, S. A., Held, P., Braunwald, E., et al. (2016) · Journal of the American College of Cardiology

Antiplatelet Therapy and Cardiovascular DiseasesAcute Myocardial Infarction Research

Cited by 216

Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk

Bergmark, B. A., Marston, N. A., Prohaska, T. A., Alexander, V. J., Zimerman, A., Moura, F. A., Murphy, S. A., Goodrich, E. L., Zhang, S., Gaudet, D., et al. (2024) · New England Journal of Medicine

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 214

Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial

Charytan, D. M., Sabatine, M. S., Pedersen, T. R., Im, K., Park, J.-G., Pineda, A. L., Wasserman, S. M., Deedwania, P., Olsson, A. G., Sever, P. S., et al. (2019) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthChronic Kidney Disease and Diabetes

Cited by 210

Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF

Martinez, F. A., Serenelli, M., Nicolau, J. C., Petrie, M. C., Chiang, C.-E., Tereshchenko, S., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., et al. (2020) · Circulation

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 210